Profile data is unavailable for this security.
About the company
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).
- Revenue in USD (TTM)0.00
- Net income in USD-11.53m
- Incorporated2011
- Employees13.00
- LocationProcessa Pharmaceuticals Inc7380 Coca Cola Dr Ste 106HANOVER 21076-1789United StatesUSA
- Phone+1 (443) 776-3133
- Fax+1 (443) 288-4420
- Websitehttps://www.processapharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Panacea Life Sciences Holdings Inc | 2.76m | -7.67m | 2.08m | 40.00 | -- | -- | -- | 0.7511 | -0.4554 | -0.4554 | 0.164 | -0.5255 | 0.1537 | 1.62 | 10.13 | 69,098.25 | -42.65 | -69.04 | -- | -225.03 | -139.49 | -181.62 | -277.51 | -505.41 | 0.0285 | -2.12 | 4.79 | -- | 46.59 | -- | 12.33 | -- | -- | -- |
| Sentient Brands Holdings Inc | 0.00 | -954.07k | 2.19m | 2.00 | -- | -- | -- | -- | -0.0164 | -0.0164 | 0.00 | -0.0307 | 0.00 | 0.00 | -- | 0.00 | -460.67 | -220.36 | -- | -- | -- | 41.81 | -- | -31,451.19 | 0.0015 | -2.50 | -- | -- | -73.68 | -- | 34.98 | -- | -- | -- |
| Scisparc Ltd | 0.00 | -6.96m | 2.41m | 3.00 | -- | 6.77 | -- | -- | -1.22 | -1.51 | 0.00 | 0.0344 | 0.00 | -- | -- | 0.00 | -92.51 | -69.39 | -152.41 | -111.07 | -- | -- | -- | -527.17 | -- | -- | 0.9371 | -- | 113.73 | -- | -97.61 | -- | -- | -- |
| Marizyme Inc | 364.96k | -52.51m | 2.41m | 11.00 | -- | -- | -- | 6.61 | -0.974 | -0.974 | 0.004 | -0.0712 | 0.0125 | 1.31 | 10.00 | 33,178.18 | -179.49 | -59.02 | -742.64 | -64.47 | 70.17 | 70.38 | -14,389.19 | -9,435.92 | 0.038 | -0.6989 | 1.92 | -- | 176.59 | 99.98 | -71.22 | -- | -- | -- |
| Scorpius Holdings Inc | 9.85m | -29.57m | 2.71m | 82.00 | -- | 0.0168 | -- | 0.2754 | -183.17 | -200.56 | 53.89 | 51.92 | 0.1552 | -- | 11.08 | 120,061.60 | -49.90 | -39.37 | -59.65 | -43.18 | 64.27 | -- | -321.53 | -1,068.21 | 0.3127 | -43.94 | 0.3569 | -- | 1,789.58 | 3.84 | 1.96 | -- | 27.32 | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 3.04m | -- | -- | -- | 2.00 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
| Stemtech Corp | 5.37m | -5.11m | 3.11m | 45.00 | -- | -- | -- | 0.5798 | -0.0518 | -0.0518 | 0.0529 | -0.0359 | 1.33 | 8.39 | 42.31 | -- | -126.26 | -- | -- | -- | 77.87 | -- | -95.16 | -- | 0.065 | -2.59 | -- | -- | 7.94 | -- | 36.45 | -- | -- | -- |
| China Pharma Holdings Inc | 6.25m | -4.40m | 3.43m | 231.00 | -- | 0.4633 | -- | 0.5494 | -0.6254 | -0.6254 | 0.6379 | 0.4317 | 0.417 | 2.34 | 23.57 | 27,047.32 | -29.39 | -29.66 | -59.89 | -55.25 | -25.89 | 6.47 | -70.48 | -73.09 | 0.2449 | -21.22 | 0.3494 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| NovaBay Pharmaceuticals Inc | 12.02m | -15.98m | 3.44m | 24.00 | -- | -- | -- | 0.2865 | -65.73 | -65.91 | 21.94 | -0.4577 | 1.21 | 2.29 | 7.59 | 500,958.30 | -105.75 | -61.51 | -205.52 | -83.89 | 58.55 | 59.99 | -87.67 | -86.47 | 0.4302 | -- | 8.81 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
| Processa Pharmaceuticals Inc | 0.00 | -11.53m | 3.59m | 13.00 | -- | 0.9658 | -- | -- | -4.86 | -4.86 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -176.99 | -84.35 | -209.96 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0022 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| CYANOTECH CORP | 23.82m | -5.10m | 3.83m | 77.00 | -- | 0.3585 | -- | 0.1607 | -0.7549 | -0.7549 | 3.56 | 1.53 | 0.8895 | 2.05 | 12.12 | 309,389.60 | -19.04 | -3.46 | -29.60 | -4.46 | 24.72 | 34.54 | -21.41 | -3.58 | 0.3354 | -6.61 | 0.377 | -- | -0.4616 | -5.24 | -53.11 | -- | -6.42 | -- |
| Titan Pharmaceuticals Inc | 4.00k | -5.46m | 3.99m | 4.00 | -- | 0.9983 | -- | 996.52 | -6.59 | -6.59 | 0.0049 | 4.37 | 0.0016 | -- | 0.1702 | 1,000.00 | -211.58 | -96.80 | -368.99 | -156.65 | -- | -- | -136,525.00 | -406.26 | -- | -309.96 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| Sonoma Pharmaceuticals Inc | 12.70m | -4.56m | 4.15m | 172.00 | -- | 0.5921 | -- | 0.3269 | -10.07 | -10.07 | 20.98 | 5.24 | 0.859 | 2.91 | 4.47 | 73,831.40 | -30.85 | -29.36 | -41.88 | -40.65 | 38.17 | 38.00 | -35.91 | -30.93 | 2.47 | -- | 0.0394 | -- | -4.05 | -7.66 | 6.13 | -- | -29.84 | -- |
| Tian'an Pharmaceutical Co Ltd | 10.65m | 3.14m | 4.16m | -- | 0.0232 | 0.005 | 1.14 | 0.3906 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Biofrontera Inc | 35.24m | -13.51m | 4.55m | 85.00 | -- | 0.3829 | -- | 0.129 | -5.29 | -5.29 | 12.12 | 2.14 | 1.21 | 1.97 | 7.27 | 414,623.50 | -46.20 | -- | -113.24 | -- | 47.75 | -- | -38.33 | -- | 1.46 | -3.53 | 0.0264 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Processa Pharmaceuticals Inc's reporting currency: US Dollar USD
1.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 24.43k | 0.75% |
| Geode Capital Management LLCas of 30 Jun 2024 | 17.24k | 0.53% |
| Tower Research Capital LLCas of 30 Jun 2024 | 3.00k | 0.09% |
| Wells Fargo Clearing Services LLCas of 30 Jun 2024 | 154.00 | 0.01% |
| The Main Street Group Ltd.as of 30 Jun 2024 | 100.00 | 0.00% |
| Allworth Financial LPas of 30 Sep 2024 | 85.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 21.00 | 0.00% |
| RBC Dominion Securities, Inc.as of 30 Jun 2024 | 4.00 | 0.00% |
| MacroView Investment Management LLCas of 30 Sep 2024 | 1.00 | 0.00% |
| Sabby Management LLCas of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
